UBS Group Analysts Give Novartis (NOVN) a CHF 82 Price Target

UBS Group set a CHF 82 target price on Novartis (VTX:NOVN) in a report released on Tuesday, www.boersen-zeitung.de reports. The firm currently has a neutral rating on the stock.

Several other equities research analysts have also recently issued reports on NOVN. Barclays set a CHF 70 target price on Novartis and gave the stock a sell rating in a research note on Monday, June 25th. Cfra set a CHF 88 target price on Novartis and gave the stock a buy rating in a research note on Friday, June 29th. Deutsche Bank set a CHF 89 target price on Novartis and gave the stock a neutral rating in a research note on Tuesday, July 3rd. JPMorgan Chase & Co. set a CHF 84 target price on Novartis and gave the stock a neutral rating in a research note on Tuesday, July 17th. Finally, Berenberg Bank set a CHF 90 target price on Novartis and gave the stock a neutral rating in a research note on Friday, June 29th. Eleven analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The stock has a consensus rating of Hold and an average price target of CHF 88.86.

NOVN stock opened at CHF 78.38 on Tuesday. Novartis has a 52-week low of CHF 72.45 and a 52-week high of CHF 88.30.

About Novartis

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Featured Story: How to calculate the intrinsic value of a stock

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply